Boston, MA – Strand Therapeutics has announced the appointment of Kunal Bhatia as Chief Financial Officer. About Strand Therapeutics: Strand Therapeutics is a clinical-stage biotechnology company pioneering breakthrough mRNA therapeutics with advanced targeted delivery systems designed for solid tumors, autoimmune diseases, and blood cancers. The company develops programmable, autonomous mRNA medicines that activate precisely within diseased cells, leveraging synthetic biology and genetic circuits to deliver multi-functional, potentially curative treatments. Their platform enables intelligent, tumor-targeted therapies, including intratumoral self-replicating mRNA encoding interleukin-12, which has advanced into Phase 1 clinical evaluation for melanoma, triple-negative breast cancer, and other solid tumors. Strand Therapeutics holds a strong market position as an innovator in immuno-oncology, with a broad pipeline spanning intratumoral, systemic, and immune cell engineering modalities. Notable achievements include significant funding of over $103 million and a focus on transforming patient lives through precise, long-acting mRNA solutions.

For more information visit: https://www.strandtx.com/

Strand Therapeutics
21-27 Burlington Ave
Boston, MA 2215
Phone: 617-993-9271
LinkedIn Page: https://www.linkedin.com/company/strandtx/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved